| 2025-10-30 |
详情>>
股本变动：
变动后总股本26712.58万股
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益17.65美元,归母净利润47.23亿美元,同比去年增长134.98%
|
| 2025-10-30 |
财报披露：
美东时间 2025-10-30 盘前发布财报
|
| 2025-10-03 |
详情>>
内部人交易：
Evanko Brian C共交易3笔
|
| 2025-07-31 |
详情>>
业绩披露：
2025年中报每股收益10.63美元,归母净利润28.55亿美元,同比去年增长124.63%
|
| 2025-05-02 |
详情>>
业绩披露：
2025年一季报每股收益4.88美元,归母净利润13.23亿美元,同比去年增长577.62%
|
| 2025-03-14 |
股东大会：
将于2025-04-23召开股东大会
会议内容 ▼▲
- 1.Election of eleven director nominees named in this Proxy Statement for one-year terms to expire at the next annual meeting of shareholders.
2.Advisory approval of executive compensation.
3.Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2025.
4.Shareholder Proposal – Support special shareholder meeting improvement, if properly presented.
5.Consideration of any other business properly brought before the meeting.
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益12.25美元,归母净利润34.34亿美元,同比去年增长-33.5%
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益21.66美元,归母净利润67.04亿美元,同比去年增长24.84%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益7.13美元,归母净利润20.10亿美元,同比去年增长-51.39%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益4.48美元,归母净利润12.71亿美元,同比去年增长-53.39%
|
| 2024-08-01 |
详情>>
业绩披露：
2023年中报每股收益9.24美元,归母净利润27.27亿美元,同比去年增长-0.98%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.97美元,归母净利润-2.77亿美元,同比去年增长-121.86%
|
| 2024-03-15 |
股东大会：
将于2024-04-24召开股东大会
会议内容 ▼▲
- 1.Election of twelve director nominees named in this Proxy Statement for one-year terms to expire at the next annual meeting of shareholders.
2.Advisory approval of executive compensation.
3.Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2024.
4.Shareholder Proposal – Improve the shareholder right to call a special shareholder meeting, if properly presented.
5.Shareholder Proposal – Report to shareholders on risks created by the Company's diversity, equity, and inclusion efforts, if properly presented.
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益17.57美元,归母净利润51.64亿美元,同比去年增长-22.97%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益14.03美元,归母净利润41.35亿美元,同比去年增长-24.97%
|
| 2023-03-17 |
股东大会：
将于2023-04-26召开股东大会
会议内容 ▼▲
- 1.Election of eleven director nominees named in this Proxy Statement for one-year terms to expire at the next annual meeting of shareholders.
2.Advisory approval of executive compensation.
3.Advisory approval of the frequency of future advisory votes on executive compensation.
4.Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2023.
5.Approval of an amendment to our Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted pursuant to recent amendments to the Delaware General Corporation Law.
6.Shareholder Proposal – Special shareholder meeting improvement, if properly presented.
7.Shareholder Proposal – Political contributions report, if properly presented.
|
| 2022-03-18 |
股东大会：
将于2022-04-27召开股东大会
会议内容 ▼▲
- 1.Election of eleven director nominees named in this Proxy Statement for one-year terms to expire at the next annual meeting of shareholders.
2.Advisory approval of executive compensation.
3.Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2022.
4.Shareholder Proposal – Special shareholder meeting improvement, if properly presented.
5.Shareholder Proposal – Gender pay gap report, if properly presented.
6.Shareholder Proposal – Political contributions report, if properly presented.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-19 |
股东大会：
将于2021-04-28召开股东大会
会议内容 ▼▲
- 1.Election of twelve director nominees named in this Proxy Statement for one-year terms to expire at the next annual meeting of shareholders.
2.Advisory approval of executive compensation.
3.Approval of the Amended and Restated Cigna Long-Term Incentive Plan.
4.Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2021.
5.Shareholder Proposal – Shareholder right to act by written consent, if properly presented.
6.Shareholder Proposal – Gender pay gap report, if properly presented.
7.Shareholder Proposal – Board ideology disclosure policy, if properly presented.
|
| 2020-03-13 |
股东大会：
将于2020-04-22召开股东大会
会议内容 ▼▲
- 1.Election of twelve director nominees named in this Proxy Statement for one-year terms to expire at the next annual meeting of shareholders
2.Advisory approval of executive compensation.
3.Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2020.
4.Shareholder Proposal Shareholder right to call a special meeting, if properly presented.
5.Shareholder Proposal Gender pay gap report, if properly presented.
|
| 2020-02-26 |
除权日：
美东时间 2020-03-09 每股派息0.04美元
|
| 2019-03-15 |
股东大会：
将于2019-04-24召开股东大会
会议内容 ▼▲
- 1.Election of thirteen director nominees named in this Proxy Statement for one-year terms to expire at the next annual meeting of shareholders.
2.Advisory approval of executive compensation.
3.Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2019.
4.Shareholder Proposal — Increase shareholder rights to include action by written consent, if properly presented.
5.Shareholder Proposal — Cyber risk report, if properly presented.
6.Shareholder Proposal — Gender pay gap report, if properly presented.
|
| 2019-02-27 |
除权日：
美东时间 2019-03-08 每股派息0.04美元
|
| 2018-03-16 |
股东大会：
将于2018-04-25召开股东大会
会议内容 ▼▲
- 1.Election of nine director nominees named in this Proxy Statement for one-year terms to expire at the next annual meeting of shareholders.
2.Advisory approval of executive compensation.
3.Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2018.
4.Approval of an amendment to the Company’s Restated Certificate of Incorporation to eliminate the supermajority voting requirement.
|
| 2017-03-17 |
股东大会：
将于2017-04-26召开股东大会
会议内容 ▼▲
- 1.Election of seven director nominees for one-year terms expiring in April 2018.
2.Advisory approval of executive compensation.
3.Advisory approval of the frequency of future advisory votes on executive compensation.
4.Approval of the Amended and Restated Cigna Long-Term Incentive Plan.
5.Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2017.
6.Consideration of a shareholder proposal, if properly presented.
|
| 2016-03-18 |
股东大会：
将于2016-04-27召开股东大会
会议内容 ▼▲
- 1.Election of four director nominees for one-year terms expiring in April 2017.
2.Advisory approval of executive compensation.
3. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2016.
|
| 2015-10-28 |
股东大会：
将于2015-12-03召开股东大会
会议内容 ▼▲
- 1.a proposal to adopt the merger agreement;
2.a non-binding, advisory proposal to approve the compensation that may be paid or become payable to Cigna’s named executive officers in connection with the completion of the merger;
3.a proposal to adjourn the Cigna special meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes to adopt the merger agreement at the time of the Cigna special meeting.
|